ATR and urinary bladder carcinoma: Considering the deficiency of G1 phase checkpoint in cancer cells and the important roles of Cdc6 and ATR in chemo-resistant cancer cells, Cdc6 may be a potential specific therapeutic target for bladder cancer, especially for CDDP-resistant bladder cancer.